The role of the RhoA/Rho kinase pathway in anti‑angiogenesis and its potential value in prostate cancer (Review)

Chen,Weihua; Mao,Kaili; Liu,Zhongmin; Dinh‑Xuan,Anh  Tuan

doi:10.3892/ol.2014.2471

The role of the RhoA/Rho kinase pathway in anti‑angiogenesis and its potential value in prostate cancer (Review)

Authors:
- Weihua Chen
- Kaili Mao
- Zhongmin Liu
- Anh Tuan Dinh‑Xuan
View Affiliations

Affiliations: Department of Clinical Physiology, Medical School, Cochin Hospital, Paris Descartes University, EA 2511, Paris 75014, France, Clinical and Translational Research Center, Tongji University, School of Medicine, Shanghai East Hospital, Shanghai 200120, P.R. China
Published online on: August 21, 2014 https://doi.org/10.3892/ol.2014.2471
Pages: 1907-1911

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) remains a major cause of mortality among males in western countries, with little change in mortality rates observed over the past 25 years. Despite recent advances in therapy, treatment options for metastatic castration‑resistant disease remain limited. In terms of chemotherapy, only the combination of docetaxel and prednisone has been shown to improve survival in these patients, but duration of response to therapy is short. There is a continuing unmet need for new systemic interventions that act either alone or synergistically with chemotherapy in patients with progressive PCa. Angiogenesis plays a critical role in tumor growth and metastasis in PCa. Several strategies have been used to target angiogenesis; however, it is becoming increasingly apparent that current anti‑angiogenic therapies frequently achieve only modest effects in clinical settings. The RhoA/Rho kinase (ROCK) pathway plays a crucial role in the process of angiogenesis in PCa, and studies have demonstrated that ROCK inhibitors decrease VEGF‑induced angiogenesis and tumor cell growth. However, further research is required to fully elucidate the molecular mechanisms involved in this pathway, and the potential value of modulating these mechanisms in the treatment of PCa. This study reviews the current understanding of the role of the RhoA/ROCK pathway in the process of angiogenesis in PCa, and the potential of this pathway as a therapeutic target in the future.

View Figures

View References

1	Bubendorf L, Schöpfer A, Wagner U, et al: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 31:578–583. 2000.
2	Roehl KA, Han M, Ramos CG, Antenor JA and Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 172:910–914. 2004.
3	Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW and Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 167:528–534. 2002.
4	Daneshgari F and Crawford ED: Endocrine therapy of advanced carcinoma of the prostate. Cancer. 71:1089–1097. 1993.
5	Eymard JC, Oudard S, Gravis G, et al: Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 106:974–978. 2010.
6	Folkman J, Cole P and Zimmerman S: Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg. 164:491–502. 1966.
7	Banerjee S, Dowsett M, Ashworth A and Martin LA: Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol. 4:536–550. 2007.
8	Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.
9	Bigler SA, Deering RE and Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol. 24:220–226. 1993.
10	Stefanou D, Batistatou A, Kamina S, Arkoumani E, Papachristou DJ and Agnantis NJ: Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo. 18:155–160. 2004.
11	Weidner N, Carroll PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 143:401–409. 1993.
12	Borre M, Offersen BV, Nerstrom B and Overgaard J: Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer. 78:940–944. 1998.
13	Brawer MK, Deering RE, Brown M, Preston SD and Bigler SA: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer. 73:678–687. 1994.
14	Bostwick DG, Wheeler TM, Blute M, et al: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology. 48:47–57. 1996.
15	Silberman MA, Partin AW, Veltri RW and Epstein JI: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer. 79:772–779. 1997.
16	Bono AV, Celato N, Cova V, Salvadore M, Chinetti S and Novario R: Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis. 5:123–127. 2002.
17	Byrne AM, Bouchier-Hayes DJ and Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 9:777–794. 2005.
18	Dvorak HF, Detmar M, Claffey KP, Nagy JA, van de Water L and Senger DR: Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol. 107:233–235. 1995.
19	Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D and Freeman MR: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology. 54:523–527. 1999.
20	George DJ, Halabi S, Shepard TF, et al: Cancer and Leukemia Group B 9480: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 7:1932–1936. 2001.
21	Peyromaure M, Camparo P, Badoual C, Descazeaud A and Dinh-Xuan AT: The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy. BJU Int. 99:1150–1153. 2007.
22	Bok RA, Halabi S, Fei DT, et al: Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer research. 61:2533–2536. 2001.
23	Green MM, Hiley CT, Shanks JH, et al: Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys. 67:84–90. 2007.
24	Huss WJ, Hanrahan CF, Barrios RJ, Simons JW and Greenberg NM: Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 61:2736–2743. 2001.
25	Wennerberg K, Rossman KL and Der CJ: The Ras superfamily at a glance. J Cell Sci. 118:843–846. 2005.
26	Bustelo XR, Sauzeau V and Berenjeno IM: GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays. 29:356–370. 2007.
27	Etienne-Manneville S and Hall A: Rho GTPases in cell biology. Nature. 420:629–635. 2002.
28	Bourne HR, Sanders DA and McCormick F: The GTPase superfamily: conserved structure and molecular mechanism. Nature. 349:117–127. 1991.
29	Bourne HR, Sanders DA and McCormick F: The GTPase superfamily: a conserved switch for diverse cell functions. Nature. 348:125–132. 1990.
30	Spiering D and Hodgson L: Dynamics of the Rho-family small GTPases in actin regulation and motility. Cell Adh Migr. 5:170–180. 2011.
31	Horowitz S, Binion DG, Nelson VM, et al: Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 292:G1323–G1336. 2007.
32	Ming XF, Barandier C, Viswambharan H, et al: Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation. 110:3708–3714. 2004.
33	Somlyo AP and Somlyo AV: Ca2⁺ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases and myosin phosphatase. Physiological reviews. 83:1325–1358. 2003.
34	Pertz O, Hodgson L, Klemke RL and Hahn KM: Spatiotemporal dynamics of RhoA activity in migrating cells. Nature. 440:1069–1072. 2006.
35	Kurokawa K and Matsuda M: Localized RhoA activation as a requirement for the induction of membrane ruffling. Mol Biol Cell. 16:4294–4303. 2005.
36	Machacek M, Hodgson L, Welch C, et al: Coordination of Rho GTPase activities during cell protrusion. Nature. 461:99–103. 2009.
37	Sakamoto S, Ryan AJ and Kyprianou N: Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem. 103:691–708. 2008.
38	Mehta D and Malik AB: Signaling mechanisms regulating endothelial permeability. Physiol Rev. 86:279–367. 2006.
39	Dudek SM and Garcia JG: Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol (1985). 91:1487–1500. 2001.
40	Sun H, Breslin JW, Zhu J, Yuan SY and Wu MH: Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation. 13:237–247. 2006.
41	Kiosses WB, Daniels RH, Otey C, Bokoch GM and Schwartz MA: A role for p21-activated kinase in endothelial cell migration. J Cell Biol. 147:831–844. 1999.
42	van Nieuw Amerongen GP, Koolwijk P, Versteilen A and van Hinsbergh VW: Involvement of RhoA/Rho kinase signaling in VEGF-induced endothelial cell migration and angiogenesis in vitro. Aterioscler Thromb Vasc Biol. 23:211–217. 2002.
43	Zhao L, Xu G, Zhou J, et al: The effect of RhoA on human umbilical vein endothelial cell migration and angiogenesis in vitro. Oncol Rep. 15:1147–1152. 2006.
44	Van Aelst L and D’Souza-Schorey C: Rho GTPases and signaling networks. Genes Dev. 11:2295–2322. 1997.
45	Glotzer M: Animal cell cytokinesis. Annu Rev Cell Dev Biol. 17:351–386. 2001.
46	Bobak D, Moorman J, Guanzon A, Gilmer L and Hahn C: Inactivation of the small GTPase Rho disrupts cellular attachment and induces adhesion-dependent and adhesion-independent apoptosis. Oncogene. 15:2179–2189. 1997.
47	Petrache I, Crow MT, Neuss M and Garcia JG: Central involvement of Rho family GTPases in TNF-alpha-mediated bovine pulmonary endothelial cell apoptosis. Biochem Biophys Res Commun. 306:244–249. 2003.
48	Yin L, Morishige K, Takahashi T, et al: Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther. 6:1517–1525. 2007.
49	Bryan BA, Dennstedt E, Mitchell DC, et al: RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J. 24:3186–3195. 2010.
50	Montesano R, Orci L and Vassalli P: In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol. 97:1648–1652. 1983.
51	Ghosh K, Thodeti CK, Dudley AC, Mammoto A, Klagsbrun M and Ingber DE: Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. Proc Natl Acad Sci USA. 105:11305–11310. 2008.
52	Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE and Somlyo AP: Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun. 269:652–659. 2000.
53	Somlyo AV, Phelps C, Dipierro C, et al: Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J. 17:223–234. 2003.
54	Wu Y, He L, Zhang L, et al: Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway. J Pharmacol Exp Ther. 339:403–411. 2011.
55	Shimokawa H, Hiramori K, Iinuma H, et al: Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 40:751–761. 2002.
56	Fukumoto Y, Matoba T, Ito A, et al: Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 91:391–392. 2005.